How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: VX-407 (drug)
How long the study runs: Study runs about 25 months (dates as stated)
About the drug or intervention: VX-407 — drug: Tablets for oral administration.
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years to 65 Years
Who: All
Number of participants: 26
Started: 2025-11-19
Last checked: 2026-09

Plain English Summary

What is this study?

• Testing a new treatment for autosomal dominant polycystic kidney disease (adpkd)
• Phase2 - 26 participants
• The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407

Who can take part?

• Ages 18 Years to 65 Years
• Diagnosed with autosomal dominant polycystic kidney disease (adpkd)

Where?

• Birmingham - Queen Elizabeth Hospital Birmingham
• London - King's College Hospital - Pulmonology
• London - Royal Free Hospital - Nephrology
• London - St George's Hospital London - Nephrology
• +2 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years - 65 Years
Who can join: All genders

Biomarkers mentioned

eGFR

What the study is looking for

✓A pre-existing diagnosis of ADPKD as defined in the protocol
✓Willing and able to comply with scheduled visits and other study procedures
✓Participants with ADPKD with Mayo imaging classification (MIC) status of 1B (with htTKV ≥250 mL/m), 1C, 1D, or 1E...
✓Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73...

Who cannot take part

✗History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the...
✗History of solid organ or bone marrow transplantation or nephrectomy
✗Ongoing kidney replacement therapy or planning to start kidney replacement therapy within 12 months of screening
✗Other protocol defined Inclusion/Exclusion criteria will apply.

See the full criteria

Key Inclusion Criteria: * A pre-existing diagnosis of ADPKD as defined in the protocol * Willing and able to comply with scheduled visits and other study procedures * Participants with ADPKD with Mayo imaging classification (MIC) status of 1B (with htTKV ≥250 mL/m), 1C, 1D, or 1E confirmed by abdominal MRI obtained during screening * Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73 square meter (m\^2) Key Exclusion Criteria: * History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD * History of solid organ or bone marrow transplantation or nephrectomy * Ongoing renal replacement therapy or planning to start renal replacement therapy within 12 months of screening Other protocol defined Inclusion/Exclusion criteria will apply.